多克萨佐辛可以缓解慢性面部疼痛
Karin N Westlund1,2, Bingye Xue1, Sabrina L McIlwrath1
1Research Service, New Mexico VA Health Care System, Albuquerque, NM 87108, USA.
International journal of molecular sciences
|March 14, 2026
概括
作为α-1抗剂的多克萨佐辛,通过调节质神经元相互作用,在老鼠模型中逆转了疼痛和焦虑. 这表明,noradrenergic系统功能从促进疼痛转向抑制的潜在转变.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 疼痛研究 疼痛研究
背景情况:
- 诺亚上腺系统,特别是α-2 (NAα2) 和α-1 (NAα1) 受体,在疼痛处理中起着双重作用.
- 急性疼痛涉及NAα2-介导的抑制,而慢性疼痛可以涉及由座驱动的NAα1-介导的疼痛促进.
研究的目的:
- 研究选择性NAα1受体对抗剂多克萨佐辛对慢性炎症性疼痛和相关行为的影响.
- 探索潜在的机制,包括质激活和神经化学变化,以及潜在的性别差异.
主要方法:
- 使用慢性炎症三角神经压缩 (FRICT-ION) 的老鼠模型.
- 在两周的时间里给大鼠服用缓释多克萨佐辛.
- 评估了面部过敏,类似焦虑的行为 (升高的零迷宫),认知功能 (新的识别) 和质激活标记 (甲素B,GFAP).
主要成果:
- 在雄性和雌性大鼠中,多克萨佐辛逆转了面部过敏症.
- 焦虑仅在雄性大鼠中降低,而新奇的识别只在雌性大鼠中得到改善.
- 多克萨佐辛降低了体感皮质和海马体中的星球细胞激活,减少了质神经元相互作用和疼痛行为.
- 在雄性大鼠中,提升的胸腺化学物质CXCL7水平仅由多克萨佐辛降低.
结论:
- 与多克萨佐辛的NAα1受体对抗作用可以通过减少质激活和恢复更抑制的诺拉德仁基基调来改善慢性炎症性疼痛.
- 性别对焦虑和认知行为的特异性影响突显了诺亚上腺系统及其调节的复杂性.
- 研究结果表明,准NAα1受体可能会将位的作用从促进疼痛转变为抑制疼痛.
相关概念视频
Analgesia and Pain Management
2.7K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.7K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.3K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
Centrally Acting Muscle Relaxants: Therapeutic Uses
1.5K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.5K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
4.8K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.8K


